Plan d’Accès©e-SIRIC... · 14H30 : Radiothérapie personnalisée des cancers de la prostate....

2
Plan d’Accès Montpellier SupAgro 2, place Pierre Viala 34060 MONTPELLIER Cedex 01 Secrétariat du Pr Marc Ychou I.C.M - Val d’Aurelle - 208 rue des Apothicaires Parc Euromédecine - 34298 Montpellier cedex 5 Timbre

Transcript of Plan d’Accès©e-SIRIC... · 14H30 : Radiothérapie personnalisée des cancers de la prostate....

Page 1: Plan d’Accès©e-SIRIC... · 14H30 : Radiothérapie personnalisée des cancers de la prostate. David Azria (ICM) 14H50 : CTC et cancers localisés de la prostate. 15H20 : Recherche

Plan d’AccèsMontpellier SupAgro2, place Pierre Viala34060 MONTPELLIER Cedex 01

Secrétariat du Pr Marc YchouI.C.M - Val d’Aurelle - 208 rue des ApothicairesParc Euromédecine - 34298 Montpellier cedex 5

Timbre

Page 2: Plan d’Accès©e-SIRIC... · 14H30 : Radiothérapie personnalisée des cancers de la prostate. David Azria (ICM) 14H50 : CTC et cancers localisés de la prostate. 15H20 : Recherche

08H45 : Introduction : Marc Ychou (SIRIC Montpellier Cancer)

09H00 : Glycosylation et cancer. Norbert Bakalara (INM)

09H30 : Impact del’ecto-ATPase CD39 sur la réponse immunitaire anti tumorale. Nathalie Bonnefoy (IRCM)

10H00 : EMT, plasticité et tumorigénicité. Alain Puisieux (CRCL, Lyon)

10H30 - 11H : Pause

14H00 : Génétique et cancer de la prostate. Olivier Cussenot (Paris)

14H30 : Radiothérapie personnalisée des cancers de la prostate.David Azria (ICM)

14H50 : CTC et cancers localisés de la prostate.Catherine Alix-Panabières (IRB), Stéphane Droupy (CHU Nîmes)

15H20 : Recherche d’alternatives thérapeutiques pour contourner la résistance des cancers de la prostate aux traitements anticancéreux.Philippe Pourquier (IRCM)

15H40 : Les protocoles régionaux de recherche en onco-urologie : perspectives 2014-2016. Xavier Rebillard ( Beausoleil )

16H00 -16H30: Pause

11H00 : Introduction. Grégory Ninot (Epsylon)

11H10 : Activités physiques et cancer.Kerry Courneya (Edmonton, Alberta Canada)

13H -14H : Déjeuner - buffet

16H30 : L’ADN circulant : émergence d’un outil diagnostique, prédictif et pronostique en oncologie digestive. Alain Thierry (IRCM)

17H : Caractérisation génomique en routine et traitement personnalisé : MOST et PROFILER. Jean-Yves Blay (Lyon)

17H30 : Marqueurs cellulaires: Identification et validation des biomarqueurs du stress réplicatif. Angelos Constantinou (IGH)

14H - 16H Focus sur une pathologie d’organe : le cancer de la prostateModérateurs : David Azria (ICM), Xavier Rebillard (Beausoleil)

16H30 - 18H Caractérisation génotypique et phénotypique des tumeurs : vers une médecine personnalisée ?Modérateurs : William Jacot (ICM), Thierry Maudelonde (CHRU)

18H Conclusion

9H - 10H30Contact de la cellule cancéreuse avec son environnementModérateurs : Marc Sitbon (IGMM) - Philippe Jay (IGF)

PROGRAMME 11H - 12HConférence SHS : Activités physiques et cancerModérateur : Gilles Romieu (ICM)

12H - 13H Session institutionnelle Les actions à 18 mois du SIRIC : Marc YchouEn présence des représentants des 7 institutions du consortium SIRIC : ICM, CHRU, INSERM, CNRS, UM1, UM2, UM3.


The effects of height and BMI on prostate cancer …ecite.utas.edu.au/104094/2/104094 print version.pdfMethods We conducted a case–control study based on 20,848 prostate cancers

The effects of height and BMI on prostate cancer …ecite.utas.edu.au/104094/2/104094 print version.pdfMethods We conducted a case–control study based on 20,848 prostate cancers

Nutrition During Chemotherapy Part 1- Nutrient Needs...maintain good nutrition –Breast –Prostate –Some colon cancers • Patients with other kinds of cancers have more trouble

Nutrition During Chemotherapy Part 1- Nutrient Needs...maintain good nutrition –Breast –Prostate –Some colon cancers • Patients with other kinds of cancers have more trouble

Company PresentationFY2021 EN 202007 · TOP 4 Cancers Treated Olympus provides products/solutions for lung, stomach, colon and prostate cancers - the top 4* highest incidence of cancers

Company PresentationFY2021 EN 202007 · TOP 4 Cancers Treated Olympus provides products/solutions for lung, stomach, colon and prostate cancers - the top 4* highest incidence of cancers

Prostate Cancer Screening Update 2019 · • PSA may miss rapidly growing, life threatening prostate cancers • 30% of men with prostate cancer and PSA >4.0 ng/mL already have disease

Prostate Cancer Screening Update 2019 · • PSA may miss rapidly growing, life threatening prostate cancers • 30% of men with prostate cancer and PSA >4.0 ng/mL already have disease

3. Childhood Cancers - faculty.washington.edufaculty.washington.edu/fvega/download/Week 1 Mehanisms, Neoplasms/3... · Breast Lung Prostate Childhood Cancers Cancer Type Number ••

3. Childhood Cancers - faculty.washington.edufaculty.washington.edu/fvega/download/Week 1 Mehanisms, Neoplasms/3... · Breast Lung Prostate Childhood Cancers Cancer Type Number ••

Prostate Cancer Screening 9-30-20...2020/09/30  · Digital Rectal Exam 17 Prostate Cancer Screening: Digital Rectal Exam •Early cancers (T1) not palpable •Positive DRE = ninefold

Prostate Cancer Screening 9-30-20...2020/09/30  · Digital Rectal Exam 17 Prostate Cancer Screening: Digital Rectal Exam •Early cancers (T1) not palpable •Positive DRE = ninefold

PATHOLOGICAL FRACTURES - bangalorespineclinic.co.in · Common cancers which metastatise to bone Osteoblastic • Breast • • Prostate • Endothelin – 1 ILGF PTHrp Mixed •

PATHOLOGICAL FRACTURES - bangalorespineclinic.co.in · Common cancers which metastatise to bone Osteoblastic • Breast • • Prostate • Endothelin – 1 ILGF PTHrp Mixed •

Corporate Presentation November 2017 - Immunomedics€“ Metastatic urothelial, metastatic castrate-resistant prostate, metastatic breast, and other cancers • Build out Company

Corporate Presentation November 2017 - Immunomedics€“ Metastatic urothelial, metastatic castrate-resistant prostate, metastatic breast, and other cancers • Build out Company

FIFTH ANNUAL OKLAHOMA Prostate & Urologic Cancers … · cancer care and integration of new technology in the evaluation and treatment of prostate cancer and urologic cancers patients.

FIFTH ANNUAL OKLAHOMA Prostate & Urologic Cancers … · cancer care and integration of new technology in the evaluation and treatment of prostate cancer and urologic cancers patients.

NCI–Frederick - National Institutes of Health Alan Rein: No XMRV DNA in ~160 prostate cancers; no XMRV antigens in sections from ~600 prostate cancers, developed cell lines to detect

NCI–Frederick - National Institutes of Health Alan Rein: No XMRV DNA in ~160 prostate cancers; no XMRV antigens in sections from ~600 prostate cancers, developed cell lines to detect

Second Oklahoma Prostate and Urologic Cancers …...09.24.16 Second Oklahoma Prostate and Urologic Cancers Symposium 6:30 am - 3 pm / Saturday, Sept. 24, 2016 SAMIS EDUCATION CENTER,

Second Oklahoma Prostate and Urologic Cancers …...09.24.16 Second Oklahoma Prostate and Urologic Cancers Symposium 6:30 am - 3 pm / Saturday, Sept. 24, 2016 SAMIS EDUCATION CENTER,

American Indian Cancer Foundation News€¦ · with prostate cancer, but prostate cancer is one of the most treatable cancers, if caught early. Native American Heritage Night with

American Indian Cancer Foundation News€¦ · with prostate cancer, but prostate cancer is one of the most treatable cancers, if caught early. Native American Heritage Night with

Association Radiothérapie-Hormonothérapie Cancers localisés et localement avancés de la prostate Michel Bolla, Camille Verry Clinique Universitaire de.

Association Radiothérapie-Hormonothérapie Cancers localisés et localement avancés de la prostate Michel Bolla, Camille Verry Clinique Universitaire de.

CANCER FACT SHEETS: PROSTATE CANCERgco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer...CANCER FACT SHEETS: PROSTATE CANCER Estimated age-standardised rates (World) in the world

CANCER FACT SHEETS: PROSTATE CANCERgco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer...CANCER FACT SHEETS: PROSTATE CANCER Estimated age-standardised rates (World) in the world

Case Study | Advanced Apps on Open Deser… · standard for detecting prostate cancer, TRUS biopsy misses 30-35% of prostate cancers with abnormally high PSA levels or a positive

Case Study | Advanced Apps on Open Deser… · standard for detecting prostate cancer, TRUS biopsy misses 30-35% of prostate cancers with abnormally high PSA levels or a positive

Androgen deprivation in prostate cancer: benefits of home ...Prostate cancer has the second highest incidence of all cancers amongst men worldwide and is the fifth leading cause of

Androgen deprivation in prostate cancer: benefits of home ...Prostate cancer has the second highest incidence of all cancers amongst men worldwide and is the fifth leading cause of

Radiobiological aspects of radiation-induced second cancers after … Trott.pdf · 2016. 9. 18. · Second cancers after radiotherapy of prostate cancer Brenner et al., Cancer 88:

Radiobiological aspects of radiation-induced second cancers after … Trott.pdf · 2016. 9. 18. · Second cancers after radiotherapy of prostate cancer Brenner et al., Cancer 88:

Private Cancer: Cancers of the Prostate, Testicles and Ovaries Paolo Aquino Internal Medicine/Pediatrics November 2005.

Private Cancer: Cancers of the Prostate, Testicles and Ovaries Paolo Aquino Internal Medicine/Pediatrics November 2005.

SCHEDULE 2 THE SERVICES - NHS England€¦ · Urological cancers include a range of tumours with different presentations including: Prostate cancer Bladder cancer Kidney cancer Prostate

SCHEDULE 2 THE SERVICES - NHS England€¦ · Urological cancers include a range of tumours with different presentations including: Prostate cancer Bladder cancer Kidney cancer Prostate

Advanced Cancer - School of Medicine · example, locally advanced pancreatic cancer is often not curable. But other locally advanced cancers, such as some prostate cancers, may be

Advanced Cancer - School of Medicine · example, locally advanced pancreatic cancer is often not curable. But other locally advanced cancers, such as some prostate cancers, may be